Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 68

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 68
---
35 | % |     |                | 105 | %  |     |             |  37 | % |
| Advance PYRUKYND®, including progressing pivotal programs in thalassemia and SCD                                                     |     |           |  35 | % |     |                | 150 | %* |     |             |  53 | % |
| Advance and diversify pipeline                                                                                                       |     |           |  15 | % |     |                | 100 | %  |     |             |  15 | % |
| Maintain financial strength and develop our strategy, organization and culture to ensure execution of the company’s long-term vision |     |           |  15 | % |     |                | 135 | %* |     |             |  20 | % |
| Total                                                                                                                                |     |           | 100 | % |     |                |     |    |     |             | 125 | % |

*Our compensation & people committee and board of directors assessed these two goals as high achievement to recognize the significant accomplishments in 2024 with respect to (i) bolstering our financial strength, including through the sale of our vorasidenib royalty rights to Royalty Pharma, and (ii) clinical and regulatory advancements made in our PYRUKYND ®programs, including achieving positive phase 3 results from both of our pivotal trials of PYRUKYND ®in thalassemia (and filing associated regulatory applications with the FDA, EMA and Kingdom of Saudi Arabia and United Arab Emirates health authorities) and completing enrollment of the phase 3 portion of our RISE UP trial of PYRUKYND ®in SCD. Our compensation & people committee also evaluates the individual performance of our NEOs, with the input of our chief executive officer in the case of the evaluation of our other NEOs, and makes recommendations to our board of directors with regard to the evaluation of our chief executive officer’s individual performance. Consistent with this process, our compensation & people committee assessed the performance of Mr. Goff in 2024 based on our relative achievement of our corporate goals as well as his individual performance and leadership in driving the execution of our strategic plans. In assessing the individual performance of our NEOs other than our chief executive officer, our compensation & people committee, with the input of our chief executive officer, considered each such officer’s individual contributions to the completion of our 2024 goals, and the officer’s individual achievements in helping